nach oben

Erschienen in:

22.05.2023

Immunotherapy in Head and Neck Cancer: Where Do We Stand?

verfasst von: Natalia G. Vallianou, Angelos Evangelopoulos, Dimitris Kounatidis, Fotis Panagopoulos, Eleni Geladari, Irene Karampela, Theodora Stratigou, Maria Dalamaga

Erschienen in: Current Oncology Reports | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Purposeof Review

Head and neck cancer (HNC) comprises a group of malignancies, amongst which squamous cell carcinoma accounts for more than 90% of the cases. HNC has been related to tobacco use, alcohol consumption, human papillomavirus, Epstein-Barr virus, air pollution, and previous local radiotherapy. HNC has been associated with substantial morbidity and mortality. This review aims to summarize the recent findings regarding immunotherapy in HNC.

Recent Findings

The recent introduction of immunotherapy, with the use of programmed death 1 (PD-1) inhibitors pembrolizumab and nivolumab, which have been FDA approved for the treatment of metastatic or recurrent head and neck squamous cell carcinoma, has changed the field in metastatic or recurrent disease. There are many ongoing trials regarding the use of novel immunotherapeutic agents, such as durvalumab, atezolizumab, avelumab, tremelimumab, and monalizumab.

Summary

In this review, we focus on the therapeutic potential of novel immunotherapy treatment modalities, such as combinations of newer immune-checkpoint inhibitors; the use of tumor vaccines such as human papillomavirus-targeted vaccines; the potential use of oncolytic viruses; as well as the latest advances regarding adoptive cellular immunotherapy. As novel treatment options are still emerging, a more personalized approach to metastatic or recurrent HNC therapy should be followed. Moreover, the role of the microbiome in immunotherapy, the limitations of immunotherapy, and the various diagnostic, prognostic, and predictive biomarkers based on genetics and the tumor microenvironment are synopsized.

Vos T, Abajobir AA, Abate KH; GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390:1211–59. https://doi.org/10.1016/S0140-6736(17)32154-2.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92. https://doi.org/10.1038/s41572-020-00224-3.CrossRefPubMedPubMedCentral

Gormley M, Creaney G, Schasche A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dental J. 2022;233(9):780–6. https://doi.org/10.1038/s41415-022-5166-x.CrossRef

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. https://doi.org/10.3322/caac.21442.CrossRefPubMed

Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–48. https://doi.org/10.1001/jamaoncol.2016.5688.CrossRefPubMedCentral

Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33:3235–42. https://doi.org/10.1200/JCO.2015.61.6995.CrossRefPubMedPubMedCentral

Yete S, D’Souza W, Saranath D. High-risk human papillomavirus in oral cancer: clinical implications. Oncology. 2018;94:133–41. https://doi.org/10.1159/000485322.CrossRefPubMed

Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–301. https://doi.org/10.1200/JCO.2011.36.4596.CrossRefPubMedPubMedCentral

10.

Shah A, Malik A, Garg A, Mair M, Nair S, Chaturvedi P. Oral sex and human papilloma virus-related head and neck squamous cell cancer: a review of the literature. Postgrad Med J. 2017;93:704–9. https://doi.org/10.1136/postgradmedj-2016-134603.CrossRefPubMed

11.

Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen C, Yang CS. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 2001;345:1877–82. https://doi.org/10.1056/nejm011610.CrossRefPubMed

12.

Sturgis EM, Pytynia KB. After the smoke clears: environmental and occupational risks for carcinoma of the upper aerodigestive tract. Cancer J. 2005;11:96–103. https://doi.org/10.1097/00130404-200503000-00002.CrossRefPubMed

13.

•• Chow LQM. Head and neck cancer. N Engl J Med. 2020;382:60–72. https://doi.org/10.1056/NEJMra171571. An expert’s opinion on the pathogenesis and treatment options regarding head and neck cancer.CrossRefPubMed

14.

Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328:184–94. https://doi.org/10.1056/NEJM199301213280306.CrossRefPubMed

15.

Peyrade F, Cupissol D, Geoffrois L, Rolland F, Borel C, Ciais C, Faivre S, Guigay J. Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes. Oral Oncol. 2013;49:482–91. https://doi.org/10.1016/j.oraloncology.2013.01.005.CrossRefPubMed

16.

Fasano M, Corte CMD, Liello RD, Viscardi G, Sparano F, Iacovino ML, Paragliola F, Piccolo A, Napolitano S, Martini G, Morgillo F, Cappabianca S, Ciardiello F. Immunotherapy for head and neck cancer: present and future. Crit Rev Oncol Hematol. 2022;174:103679. https://doi.org/10.1016/j.critrevonc.2022.103679.CrossRefPubMed

17.

• Pereiera D, Martins D, Mendes F. Immunotherapy in head and neck cancer: when, how and why? Biomedicines. 2022;10:2151. https://doi.org/10.3390/biomedicines10092151. A review article elaborating ον immunotherapy in R/MHNSCC.CrossRef

18.

Chakraborty R, Darido C, Liu F, Maselko M, Ranganathan S. Head and neck cancer immunotherapy: molecular biological aspectsof preclinical and clinical research. Cancers. 2023;15:852. https://doi.org/10.3390/cancers150300852.CrossRefPubMedPubMedCentral

19.

Spyrou N, Vallianou N, Kadillari J, Dalamaga M. The interplay of obesity, gut microbiome and diet in the immune checkpoint inhibitors therapy era. Semin Cancer Biol. 2021;73:356–76. https://doi.org/10.1016/j.semcancer.2021.05.008.CrossRefPubMed

20.

Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. 1893;10:487–511.CrossRef

21.

Carlson RD, Flickinger JC, Snook AE. Talkin’ Toxin’s From Coley’s to modern cancer immunotherapy. Toxins. 2020;12(4):241. https://doi.org/10.3390/toxins12040241.CrossRefPubMedPubMedCentral

22.

Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. A new member of the immunoglobulin family-CTLA-4. Nature. 1988;328:267–70.CrossRef

23.

Lipson EJ, Drake CG. Ipilimimab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17(22):6958–62. https://doi.org/10.1158/1078-0432.CCR-11-1595.CrossRefPubMedPubMedCentral

24.

Ishida Y. PD-1: its discovery, involvement in cancer immunotherapy and beyond. Cells. 2020;9(6):1376. https://doi.org/10.3390/cells9061376.CrossRefPubMedPubMedCentral

25.

Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119:153–9. https://doi.org/10.1038/s41416-018-0131-9.CrossRefPubMedPubMedCentral

26.

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase ii study. J Clin Oncol. 2017;35:1542–9. https://doi.org/10.1200/JCO.2016.70.1524.CrossRefPubMedPubMedCentral

27.

Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ. KEYNOTE-048 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;393:156–67. https://doi.org/10.1016/S0140-6736(18)31999-8.CrossRefPubMed

28.

Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67. https://doi.org/10.1056/NEJMoa1602252.CrossRefPubMedPubMedCentral

29.

Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7:184. https://doi.org/10.1186/s40425-019-0662-5.CrossRefPubMedPubMedCentral

30.

Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019;107:142–52. https://doi.org/10.1016/j.ejca.2018.11.015.CrossRefPubMed

31.

Colevas AD, Bahleda R, Braiteh F, Balmanoukian A, Brana I, Chau NG, Sarkar I, Molinero L, Grossman W, Kabbinavar F, Fasso M, O’Hear C, Powderly J. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Ann Oncol. 2018;29:2247–53. https://doi.org/10.1093/annonc/mdy411.CrossRefPubMed

32.

Guigay J, Lee KW, Patel MR, Daste A, Wong DJ, Goel S, Gordon MS, Gutierrez M, Balmanoukian A, Le Tourneau C, Mita A, Vansteene D, Keilholz U, Schöffski P, Grote HJ, Zhou D, Bajars M, Penel N. Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN solid tumor trial. J Immunother Cancer. 2021;9:e002998. https://doi.org/10.1136/jitc-2021-002998.CrossRefPubMedPubMedCentral

33.

Chen SW, Li SH, Shi DB, Jiang WM, Song M, Yang AK, Li YD, Bei JX, Chen WK, Zhang Q. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance. Int J Biol Markers. 2019;34(4):398–405. https://doi.org/10.1177/1724600819884722.CrossRefPubMed

34.

•• Ruffin AT, Li H, Vujanovic A, Zandberg DP, Ferris RL, Bruno TC. Improving head and neck cancer therapies by immunomodulation of the tumor microenvironment. Nat Rev Cancer. 2023;23(3):173–88. https://doi.org/10.1038/s41568-022-00531-9. An up to date manuscript on the significance of modulating the tumor microenvironment to combat HNSCC.CrossRefPubMed

35.

Dadey RE, Workman CJ, Vignali DA. A regulatory T cells in the tumor microenvironment. Adv Exp Med Biol. 2020;1273:105–34. https://doi.org/10.1007/978-3-030-49270-0-6.CrossRefPubMed

36.

Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, Pennathur A, Corry DB, Luketich JD, Lafyatis R, Chen W, Poholek AC, Bruno TC, Workman CJ, Vignali DAA. Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019;20:724–35. https://doi.org/10.1038/s41590-019-0346-9.CrossRefPubMedPubMedCentral

37.

Jie HB, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL, Ferris RL. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer. 2013;109:2629–35. https://doi.org/10.1038/bjc.2013.645.CrossRefPubMedPubMedCentral

38.

Santuray RT, Johnson DE, Grandis JR. New therapies in head and neck cancer. Trends Cancer. 2018;4:385–96. https://doi.org/10.1016/j.trecan.2018.03.006.CrossRefPubMedPubMedCentral

39.

Moskovitz J, Moy J, Ferris RL. Immunotherapy for head and neck squamous cell carcinoma. Curr Oncol Rep. 2018;20:22. https://doi.org/10.1007/s11912-018-0654-5.CrossRefPubMedPubMedCentral

40.

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1–low/negative recurrent or metastatic HNSCC. JAMA Oncol. 2019;5:195. https://doi.org/10.1001/jamaoncol.2018.4628.CrossRefPubMed

41.

Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, Clement PM, Mesia R, Kutukova S, Zholudeva L, Daste A, Caballero-Daroqui J, Keam B, Vynnychenko I, Lafond C, Shetty J, Mann H, Fan J, Wildsmith S, Morsli N, Fayette J, Licitra L. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31:942–50. https://doi.org/10.1016/j.annonc.2020.04.001.CrossRefPubMed

42.

Van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019;7:263. https://doi.org/10.1186/s40425-019-0761-3.CrossRefPubMedPubMedCentral

43.

Galot R, Tourneau CL, Saada-Bouzid E, Daste A, Even C, Debruyne PR, Henry S, Zanetta S, Rutten A, Licitra LF. A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM). Ann Oncol. 2019;30:v449–50. https://doi.org/10.1093/annonc/mdy452.CrossRef

44.

André P, Denis Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A. Anti-NKG2A MAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175:1731-43.e13. https://doi.org/10.1016/j.cell.2018.10.014.CrossRefPubMedPubMedCentral

45.

•• Ghosh S, Shah PA, Johnson FM. Novel systemic treatment modalities including immunotherapy and molecular targeted therapy for recurrent and metastatic head and neck squamous cell carcinoma. Int J Mol Sci. 2022;23:7889. https://doi.org/10.3390/ijms23147889. A very interesting update on immuno therapy in HNSCC.CrossRefPubMedPubMedCentral

46.

Ying Z, Huang XF, Xiang X. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25:947–53. https://doi.org/10.1038/s41591-019-0421-7.CrossRefPubMedPubMedCentral

47.

Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321–30.CrossRefPubMedPubMedCentral

48.

•• Damasio MPS, Nascimento CS, Andrade LM, de Oliveira VL, Calzavara-Silva CE. The role of T cells in head and neck squamous cell carcinoma: from immunity to immunotherapy. Front Oncol. 2022;12:1021609. https://doi.org/10.3389/fonc.2022.1021609.eCollection2022. An overview on the role of immunotherapy, with special interest in CAR-T cells therapy in HNSCC.CrossRefPubMedPubMedCentral

49.

Warren EA, Liu H-C, Porter CE, Liao KS, Hegde M, Yu W, et al. Abstract 574: overexpression of HER2 in head and neck cancer represents a potential target for T cell immunotherapy. Cancer Res. 2019;79:574–84. https://doi.org/10.1158/1538-7445.am2019-574.CrossRef

50.

Park YP, Jin L, Bennett KB, Wang D, Fredenburg KM, Tseng JE, Chang LJ, Huang J, Chan EKL. CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma. Oral Oncol. 2018;78:145–50. https://doi.org/10.1016/j.oraloncology.2018.01.024.CrossRefPubMedPubMedCentral

51.

Norberg SM, Hinrichs CS. Advances in adoptive cell therapy for head and neck cancer. Otolaryngol Clin N Am. 2021;54:761–8. https://doi.org/10.1016/j.ccell.2022.10.016.CrossRef

52.

Doran SL, Stevanovic´ S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, Faquin WC, Hewitt SM, Sherry RM, Yang JC, Rosenbetg SA, Hinrichs CS. T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I/II study. J Clin Oncol. 2019;37:2759–68. https://doi.org/10.1200/JCO.18.02424.CrossRefPubMedPubMedCentral

53.

Marcinkowski B, Stevanovic´ S, Helman SR, Norberg SM, Serna C, Jin B, Gkitsas N, Kadakia T, Warner A, Davis JL, Rooper L, Hinrichs CS. Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu lung cancer antigen-1. J Immunother Cancer. 2019;7:229. https://doi.org/10.1186/s40425-019-0678-x.CrossRefPubMedPubMedCentral

54.

Bai Y, Hui P, Du X, Su X. Updates to the antitumor mechanism of oncolytic virus. Thorac cancer. 2019;10:1031–5. https://doi.org/10.1111/1759-7714.13043.CrossRefPubMedPubMedCentral

55.

Cheng G, Dong H, Yang C, Liu Y, Wu Y, Zhu L, Tong X, Wang S. A review on the advances and challenges of immunotherapy for head and neck cancer. Cancer Cell Int. 2021;21(1):406. https://doi.org/10.1186/s12935-021-02024-5.CrossRefPubMedPubMedCentral

56.

Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373–9. https://doi.org/10.1111/cas.13027.CrossRefPubMedPubMedCentral

57.

Kohlhapp FJ, Kaufman HL. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res. 2016;22:1048–54. https://doi.org/10.1158/1078-0432.CCR-15-2667.CrossRefPubMed

58.

Cheng G, Dong H, Yang C, Liu Y, Wu Y, Zhu L, Tong X, Wang S. A review on the advances and challenges of immunotherapy for head and neck cancer. Cancer Cell Int. 2021;21:406. https://doi.org/10.1186/s12935-021-02024-5.CrossRefPubMedPubMedCentral

59.

Huang Y, Liao J, Liang F, Lin P, Wu S, Ye Y, Gao M, Chen R, Zeng H, Yin X, Jiang Y, Ouyang N, Han P, Huang X. A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma. Int Immunopharmacol. 2022;110:108846. https://doi.org/10.1016/j.intimp.2022.108846.CrossRefPubMed

60.

• Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–65. https://doi.org/10.1016/S1470-2045(16)30066-3. An original-and why not pioneering- research regarding pembrolizumab for the treatment of R/M HNSCC.CrossRefPubMed

61.

Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for recurrent squamous-cell carcinoma of the nead and neck cancer. N Engl J Med. 2016;375(19):1856–67. https://doi.org/10.1056/NEJMoa1602252.CrossRefPubMedPubMedCentral

62.

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for platinum and cetuximab-refractory head and neck cancer: results from a single-arm phase II study. J Clin Oncol. 2017;35(14):1542–9. https://doi.org/10.1200/JCO.2016.70.1524.CrossRefPubMedPubMedCentral

63.

Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Ge J, Swaby RF, Gumuscu B, Harrington K. Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE 048 Study: subgroup analysis by programmed death ligand -1 combined positive score. J Clin Oncol. 2022;40(21):2321–32. https://doi.org/10.1200/JCO.21.02198.CrossRefPubMedPubMedCentral

64.

• Yamamoto H, Watanabe Y, Maehata T, Imai K, Itoh F. Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach. Arch Toxicol. 2020;94(10):3349–57. https://doi.org/10.1007/s00204-020-02833-z. A very interesting manuscript elaborating upon the micro satellite instability in cancer.CrossRefPubMed

65.

Yang G, Zheng RY, Jin ZS. Correlations between microsatellite instability and the biological behavior of tumors. J Cancer Res Clin Oncol. 2019;145(12):2891–9. https://doi.org/10.1007/s00432-019-02942-y.CrossRefPubMedPubMedCentral

66.

Merino DM, McShane LM, Fabrizio D, Funari V, Chen S, White JR. Establishing guidelines to harmonize tumor mutational burden: in silico assessment of variation in TMB quantification across diagnostic platforms:phase 1 of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. 2020;8(1):e100147. https://doi.org/10.1136/jitc-2019-000147.CrossRef

67.

• Addeo A, Banna GL, Weiss GJ. Tumor mutation burden: from hopes to doubts. JAMA Oncol. 2019;5(7):934–5. https://doi.org/10.1002/cncy22174. A recent manuscript focusing upon tumor mutation burden and analyzing the prons and cons of this parameter.CrossRefPubMed

68.

Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–1. https://doi.org/10.1056/NEJMc1713444.CrossRefPubMedPubMedCentral

69.

Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, Philip R, Ghosh S, Theoret MR, Beaver JA, Pazdur R, Lemery SJ. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden high solid tumors. Clin Cancer Res. 2021;27(17):4685–9. https://doi.org/10.1158/1078-0432.CCR-21-0327.CrossRefPubMedPubMedCentral

70.

Sakaguchi S, Yamaguchi T, Nomura T, Omo M. Regulatory T cells and immune tolerance. Cell. 2008;133:775–87. https://doi.org/10.1016/j.cell.2008.05.009.CrossRefPubMed

71.

Castillo J, Wu E, Lowe C, Srinivasan S, McCord R, Wagle MC, Jayakar S, Edick MG, Eastham-Anderson J, Liu B, Hutchinson KE, Jones W, Stokes MP, Tarighat SS, Holcomb T, Glibicky A, Romero FA, Magnuson S, Huang SA, Plaks V, Giltnane JM, Lackner MR, Mounir Z. CBP/p300 drives the differentiation of regulatory T cells through transcriptional and non-transcriptional mechanisms. Cancer Res. 2019;79(15):3916–27. https://doi.org/10.1158/0008-5472.CAN-18-3622.CrossRefPubMed

72.

Clara JA, Monge C, Yang Y, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2020;17(4):204–32. https://doi.org/10.1038/s41571-019-0293-2.CrossRefPubMed

73.

Zhang K, Hong X, Song Z, Xu Y, Li C, Wang G, Zhang Y, Zhao X, Zhao Z, Zhao J, Huang M, Huang D, Qi C, Gao C, Cai S, Gu F, Hu Y, Xu C, Wang W, Lou Z, Zhang Y, Liu L. Identification of deleterious NOTCH mutation as novel predictor to efficacious immunotherapy in NSCLC. Clin Cancer Res. 2020;26(14):3649–61. https://doi.org/10.1158/1078-0432.CCR-19-3976.CrossRefPubMed

74.

Jiang Y, Jiang YY, Xie JJ, Mayakonda A, Hazawa M, Chen L, Xiao JF, Li CQ, Huang ML, Ding LW, Sun QY, Xu L, Kanojia D, Jeitany M, Deng JW, Liao LD, Soukiasian HJ, Berman BP, Hao JJ, Xu LY, Li EM, Wang MR, Bi XG, Lin DC, Koeffler HP. Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression. Nat Commun. 2018;9(1):3619. https://doi.org/10.1038/s41467-018-06081-9.CrossRefPubMedPubMedCentral

75.

• Zheng L, Guan Z, Xue M. TGF-β signaling pathway-based model to predict the subtype and prognosis of head and neck squamous cell carcinoma. Front Genetics. 2022;13:862860. https://doi.org/10.3389/fgene.2022.862860. A very recent manuscript focusing on the significance of TGF-β in the pathogenesis and prognosis of HNSCC.CrossRef

76.

Bell RB, Gough M, Crittenden R, Young K. Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer. J Clin Invest. 2022;132(18):e162733. https://doi.org/10.1172/JCI162733.CrossRefPubMedPubMedCentral

77.

Redman JM, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, Sinkoe A, Papanicolau-Sengos A, Lee CC, Marte JL, Turkbey E, Mydlarz W, Joshi A, London NR, Pierce M, Taylor R, Hong S, Nguyen A, Soon-Shiong P, Schlom J, Gulley JL, Allen CT. Enhanced neoepitope specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer. J Clin Invest. 2022;132(18):e161400. https://doi.org/10.1172/JCI161400.CrossRefPubMedPubMedCentral

78.

Starzer AM, Heller G, Tomasich E, Melchardt T, Feldmann K, Hatziioannou T, Traint S, Minichsdorfer C, Schwarz-Nemec U, Nackenhorst M, Müllauer L, Preusser M, Berghoff AS, Fuereder T. DNA methylation profiles differ in responders versus nonresponders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. J Immunother Cancer. 2022;10(3):e003420. https://doi.org/10.1136/jitc-2021-003420.CrossRefPubMedPubMedCentral

79.

Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. Influence of tumor mutational burden, inflammatory gene expression profile and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022;10(2):e003026. https://doi.org/10.1136/jitc-2021-003026.CrossRefPubMedPubMedCentral

80.

Anderson NM, Simon MC. Tumor microenvironment. Curr Biol. 2020;30(16):R921–5. https://doi.org/10.1016/j.cub.2020.06.081.CrossRefPubMedPubMedCentral

81.

Luo H, Xia X, Huang LB, An H, Cao M, Kim GD, Chen HN, Zhang WH, Shu Y, Kong X, Ren Z, Li PH, Liu Y, Tang H, Sun R, Li C, Bai B, Jia W, Liu Y, Zhang W, Yang L, Peng Y, Dai L, Hu H, Jiang Y, Hu Y, Zhu J, Jiang H, Li Z, Caulin C, Park J, Xu H. Pan cancer single cell analysis reveals the heterogeneity and plasticity of cancer associated fibroblasts in the tumor microenvironment. Nat Commun. 2022;13(1):6619. https://doi.org/10.1038/s41467-022-34395-2.CrossRefPubMedPubMedCentral

82.

Du K, Zou J, Wang B, Liu C, Khan M, Xie T, Huang X, Shen P, Tian Y, Yuan Y. A Metabolism-related gene prognostic index bridging metabolic signatures and antitumor immune cycling in head and neck squamous cell carcinoma. Front Immunol. 2022;13:857934. https://doi.org/10.3389/fimmu.2022.857934.CrossRefPubMedPubMedCentral

83.

Qiang W, Dai Y, Xing X, Sun X. Identification of a metabolic reprogramming-related signature associated with prognosis and immune microenvironment of head and neck squamous cell carcinoma by in silico analysis. Cancer Med. 2022;11(16):3168–81. https://doi.org/10.1002/cam4.4670.CrossRefPubMedPubMedCentral

84.

Wang X, Wu S, Liu F, Ke D, Wang X, Pan D, Xu W, Zhou L, He W. An immunogenic cell death-related classification predicts prognosis and response to immunotherapy in head and neck squamous cell carcinoma. Front Immunol. 2021;12:781466. https://doi.org/10.3389/fimmu.2021.781466.CrossRefPubMedPubMedCentral

85.

Chen X, Liu Y, Tao B, Xue X, Zhang X, Wang L, Zhong H, Zhang J, Yang S, Jiang Q. NT5E upregulation in head and neck squamous cell carcinoma: a novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment. Front Immunol. 2022;13:975847. https://doi.org/10.3389/fimmu.2022.975847.CrossRefPubMedPubMedCentral

86.

Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D, Dalamaga M. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives. Biomolecules. 2021;12(1):56. https://doi.org/10.3390/biom12010056.CrossRefPubMedPubMedCentral

87.

Vallianou N, Stratigou T, Christodoulatos GS, Tsigalou C, Dalamaga M. Probiotics, prebiotics, synbiotics, postbiotics, and obesity: current evidence, controversies, and perspectives. Curr Obes Rep. 2020;9(3):179–92. https://doi.org/10.1007/s13679-020-00379-w.CrossRefPubMed

88.

Mukherjee PK, Wang H, Retuerto M, Zhang H, Burkey B, Ghannoum MA, Eng C. Bacteriome and mycobiome associations in oral tongue cancer. Oncotarget. 2017;8(57):97273–89. https://doi.org/10.18632/oncotarget.21921.CrossRefPubMedPubMedCentral

89.

Vallianou N, Kounatidis D, Christodoulatos GS, Panagopoulos F, Karampela I, Dalamaga M. Mycobiome and cancer: what is the evidence? Cancers. 2021;13(13):3149. https://doi.org/10.3390/cancers13133149.CrossRefPubMedPubMedCentral

90.

Dorobisz K, Dorobisz T, Zdonski T. The microbiome’s influence on head and neck cancer. Curr Oncology Rep. 2023;25(3):163–71. https://doi.org/10.1007/s11912-022-01352-7.CrossRef

91.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryfel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Gut microbiome infuences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–7. https://doi.org/10.1126/science.aan3706.CrossRefPubMed

92.

Meliante PG, Barbato C, Zoccali F, Ralli M, Greco A, de Vincentiis M, Colizza A, Petrella C, Ferraguti G, Minni A. Programmed cell death-ligand 1 in head and neck squamous cell carcinoma: molecular insights, preclinical and clinical data, and therapies. Int J Mol Sci. 2022;23:15384. https://doi.org/10.3390/ijms232315384.CrossRefPubMedPubMedCentral

93.

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland A, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D. KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–28. https://doi.org/10.1016/S0140-6736(19)32591-7.CrossRefPubMed

94.

•• Mody MD, Rocco JW, Yam SS, Haddad RI, Saba NF. Head and neck cancer. Lancet. 2021;398:2289–99. https://doi.org/10.1016/S0140-6736(21)01550-6. An excellent review on the incidence, aetiologies and treatment modalities regarding head and neck cancer.CrossRefPubMed

95.

Emfietzoglou R, Spyrou N, Mantzoros CS, Dalamaga M. Could the endocrine disruptor bisphenol-A be implicated in the pathogenesis of oral and oropharyngeal cancer? Metabolic Consider Future Direct Metabol. 2019;91:61–9. https://doi.org/10.1016/j.metabol.2018.11.007.CrossRef

96.

Botticelli A, Cirillo A, Strigari L, Valentini F, Cerbelli B, Scagnoli S, Cerbelli E, Zizzari IG, Della Rocca C, D’Amati G, Polimeni A, Nuti M, Merlano MC, Mezi S, Marchetti P. Anti–PD-1 and anti–PD-L1 in head and neck cancer: a network meta-analysis. Front Immunol. 2012;12:705096. https://doi.org/10.3389/fimmu.2021.705096.CrossRef

97.

Shibata H, Zhou L, Xu N, Egloff AM, Uppaluri R. Personalized cancer vaccination in head and neck cancer. Cancer Sci. 2021;112:978–88.CrossRefPubMedPubMedCentral

Titel: Immunotherapy in Head and Neck Cancer: Where Do We Stand?
verfasst von: Natalia G. Vallianou
Angelos Evangelopoulos
Dimitris Kounatidis
Fotis Panagopoulos
Eleni Geladari
Irene Karampela
Theodora Stratigou
Maria Dalamaga
Publikationsdatum: 22.05.2023
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 8/2023
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-023-01425-1

Springer Medizin

Immunotherapy in Head and Neck Cancer: Where Do We Stand?

Abstract

Purposeof Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Update Onkologie

Springer Medizin

Abstract

Purposeof Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2023

Rational Alternatives to Fludarabine and Cyclophosphamide-Based Pre-CAR Lymphodepleting Regimens in the Pediatric and Young Adult B-ALL Setting

Hairy Cell Leukemia: Where Are We in 2023?

Diagnostic and Therapeutic Updates in Leptomeningeal Disease

Cardiotoxicities of Non-Chemotherapeutic Metastatic Breast Cancer Treatments

Correction to: Current Status of Perioperative Therapy in Muscle‑Invasive Bladder Cancer and Future Directions

Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Update Onkologie